This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.
UCB’s Vimpat (lacosamide) also gained a thumbs up in the epilepsy market, with a recommendation in partial-onset seizures with or without secondary generalisation. ... This most recent indication sees Vimpat continue on its trajectory to blockbuster
CEO outlines pipeline promise, won't write off post-Brexit UK. Mid-sized pharma company UCB has seen its epilepsy treatment Vimpat break through the $1bn+ annual revenues mark, joining its ... Vimpat is forecast to reach 1.4bn by 2022, the year its US
Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.
The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which
Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%
The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.
More from news
Approximately 7 fully matching, plus 12 partially matching documents found.
Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.
For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,
It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....